MOTS-c

FROM THE REEL TO THE RESEARCH

Can a metabolic signal translate into better performance?

These are not four versions of the same mitochondrial treatment. NAD+ participates in redox chemistry and enzyme reactions; MOTS-c is investigated as a metabolic stress signal; SS-31 binds cardiolipin; Humanin has experimental cell-survival actions. Their human evidence is also unequal and disease-specific. None of the comparisons reviewed here establishes a four-way winner for healthy-person energy, fat loss, hypertrophy or longevity, and different mechanisms do not prove a beneficial stack.

From MOTS-c vs NAD+ vs SS-31 vs Humanin · Editorial update 2026-10-16

THE MECHANISM MINUTE / EPISODE 05

A visual comparison of elamipretide (SS-31) and MOTS-c: cardiolipin, stress signaling, human trials, FDA approval, exercise claims and the evidence missing from peptide stacks.

Related comparisons (1)
Mechanisms explain possibilities. Outcomes, populations and study limitations determine what the evidence supports.

What it is & what research shows

Study example available

MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA. It is investigated in metabolic, exercise and aging biology, including pathways related to cellular energy sensing. The cited foundational study reported metabolic effects in mice and described cell-level signaling. Human observations do not equal a trial of injected MOTS-c, and no approved therapeutic use is established here. [1.1][1.2]

One selected study: Researchers examined whether and how MOTS-c affects skeletal-muscle mitochondrial function, focusing on dependence on the PGC-1α regulator and AMPK energy-sensing enzyme. Experiments used two transgenic mouse strains. A separate human experiment examined one-legged knee-extension exercise; sample sizes were not reported in the abstract. MOTS-c was administered in the mouse experiments. The abstract does not specify dose, route, treatment duration or comparator details. Mouse muscle mitochondrial performance improved, with lower reactive oxygen release and related protein damage, but no apparent change in respiratory protein content. In humans, interstitial MOTS-c increased during exercise, but its arterial–venous difference did not change. These human observations do not test MOTS-c treatment efficacy. Study limitations were not stated in the abstract. Methodological quality has not been appraised. [2.1]

Studied methods, not dosing advice. Selected evidence, not a complete literature review or formal quality appraisal. Read the study summary
Sources & reading scope

Evidence summarized on PED Evidence

5 completed summaries

1 human-study reports

0 randomized-trial candidates

2 safety-topic reports

These counts describe completed summaries on this site, not the size of the full literature. Publications can share participants; design labels are discovery metadata, not appraisals.

Filter, save and compare MOTS-c studies →

Selected study reading notes

Source-linked summaries with studied methods. These are separate from the automated summary counts above and are not formal quality appraisals.

Animal

Can muscle preservation occur without preventing overall weight loss?

Demonstrated findings

In a C26 cancer-cachexia mouse model, MOTS-c preserved quadriceps mass relative to vehicle, without preventing overall body-weight loss.

What might this mean? · interpretation

Muscle-specific effects may differ from changes on a body-weight scale.

What might this mean, and what would change the interpretation?

A cancer-cachexia mouse model does not predict muscle gain in healthy people or effects during GLP-1 treatment.

What would clarify this: Replication across models and controlled human measurements of muscle mass and function.

Mechanism to possible human relevance
Working explanation
The mouse result suggests muscle and whole-body weight may respond differently in a disease model.
Possible human implication, hypothesis
Preserving muscle in other wasting settings is worth testing; preservation during GLP treatment remains a separate hypothesis.
Evidence that would support it
Replication with function measures and controlled trials in the relevant human population.
Evidence that would challenge it
No preservation outside the original model, or mass changes without meaningful functional benefit.
More about MOTS-c: identity, safety & reference details
PeptideMitochondria
Primary research area
Mitochondria · metabolism & aging
Regulatory status
Investigational / research only
Evidence level
Preclinical · early translational
Primary mechanism
Mitochondrial-derived peptide linked to AMPK and metabolic signaling
Reference profile available · Coverage varies by section

Also known as MOTSc

What has been observed?

Selected source-linked reading notes, not the complete literature or a pooled conclusion.

Animal · Reading scope not recorded

Can muscle preservation occur without preventing overall weight loss?

In a C26 cancer-cachexia mouse model, MOTS-c preserved quadriceps mass relative to vehicle, without preventing overall body-weight loss.

Limits: A cancer-cachexia mouse model does not predict muscle gain in healthy people or effects during GLP-1 treatment.

Open primary source · Read interpretation separately
Explore outcomes for this compound
Uses & research

The cited foundational study reported metabolic effects in mice and described cell-level signaling. Human observations do not equal a trial of injected MOTS-c, and no approved therapeutic use is established here. [1][2]

Known half-life

No source-verified value in this profile yet. A treatment schedule or duration of an effect is not a drug half-life.

Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.
Evidence & important limits

The available evidence does not establish a human half-life, a safe clinical formulation, or human effectiveness for weight, muscle, endurance or longevity outcomes. Mechanistic and animal findings require direct human testing. [1][2]

Safety & evidence boundaries

Source-specific information, not a personal safety clearance or monitoring plan.

The available evidence does not establish a human half-life, a safe clinical formulation, or human effectiveness for weight, muscle, endurance or longevity outcomes. Mechanistic and animal findings require direct human testing.

Explore safety questions by system

These are literature filters, not claims that this compound causes each effect. A keyword match is not a confirmed adverse reaction.

Interactions, rare harms, long-term effects and reversibility require separate evidence. Do not infer they are absent when the sources here do not address them.

Identity, names & formulations

Canonical compound: MOTS-c · motsc

Searchable names: MOTSc

Names share a parent research page. Different esters, salts, routes and brands are not assumed to have the same half-life, indication or exposure.

Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.

Understand the evidence types

Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.

Randomized human trials
Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
Controlled human studies
Use a comparison group; allocation and confounding still matter.
Prospective human research
Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
Observational human research
Describes associations. Confounding can explain differences.
Case reports and series
Useful for unusual events and safety signals, not reliable rates or effect sizes.
Animal research
Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
Cell and tissue research
Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
Mechanistic and computational evidence
Helps explain or predict a pathway; predictions need experimental and clinical testing.
Anecdotal reports
Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.

Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.

Sources for this profile

  1. 1. Lee et al., MOTS-c and metabolic homeostasis (2015) Primary study · cell and mouse metabolic models
  2. 2. Cell Metabolism full article Full article · foundational MOTS-c study

Reference facts checked 2026-09-16. Source scope is listed above; this is not a formal quality appraisal. See each label for full prescribing information.

Browse all studies

Study model describes the source. Confidence depends on methods, replication, population and outcome.

Loading compound research…

MOTS-c study summaries

Human-first reading order. Intervention candidates are distinguished from background mentions in the library.